Frontier mental health research: psychedelics & drug studies

Key findings

• Researchers are testing psychedelic medicines, including ketamine, for addictions as part of a broader return to clinical studies of these drugs. ^{15098 15092 15085}
• Ketamine acts mainly on the brain’s glutamate system and can boost neuroplasticity — that is, the brain’s ability to change — which is one reason scientists think it might help with mental health and addiction. ¹⁵⁰⁹¹
• Evidence that ketamine helps addiction is limited. Most reports are early-stage, small, or mixed; ketamine has been included in some studies but there are not yet large, definitive trials for addiction. ^{15092 15098 15085}
• How ketamine is used matters. Preparing people, the therapy that goes with the drug, and the treatment setting strongly shape outcomes in substance-assisted therapies. ^{15065 15092}
• When ketamine is given in medical settings, serious dependence or tolerance has been uncommon in reported depression studies, but a few clear cases were recorded and long-term risk is not fully known. ^{8828 12365}
• Ketamine is also a recreational dissociative drug and is linked to the wider problem of novel psychoactive and dissociative substances, which raises public health and legal concerns. ^{15099 15087}
• Many reviews call for larger, controlled trials with longer follow-up before we can know if ketamine is a reliable, long-term treatment for addiction. ^{15098 15085 15091}
• The growing commercial interest in psychedelic treatments creates ethical and safety questions. Authors suggest the field should learn from past clinical and commercial experiences — including issues seen with ketamine use — when expanding treatments for addiction. ^{15087 15085}